Derma Sciences obtains CE Mark for Medihoney HCS dressings
Princeton, N.J.-based Derma Sciences (NSDQ:DSCI) received CE Mark approval in the European Union for the latest product in its line of Medihoney HSC (hydrogel colloidal sheet) dressings. This is the final product in the Medihoney line to receive the marking, rendering the entire line of products CE Marked.
This announcement follows the recent resignation of CEO Edward Quilty from the company’s board over violation of Nasdaq’s rules on membership of listing officers.
Syneron Medical obtains clearance for elos Plus
Syneron Medical Ltd. (NSDQ:ELOS) received FDA clearance for its new product, elos Plus, a multi-platform system that delivers various forms of aesthetic treatments. The clearance follows recent launch of the product in both Europe and Asia.
Capricor announces approval of trial for post-heart attack patients
Capricor, a Los Angeles, Calif.-based company, received FDA IND approval to begin trials for a new regenerative therapy for heart attack patients. The trial, called the Allstar study, uses cardiac-derived stem cells to repair damage caused by heart attacks.